Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 24, Issue 6, Pages 749-757
Publisher
Springer Nature
Online
2018-05-29
DOI
10.1038/s41591-018-0053-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
- (2018) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
- (2017) James J. Hsieh et al. EUROPEAN UROLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- COX2/mPGES1/PGE2pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
- (2017) Victor Prima et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
- (2017) Helen Ha et al. Theranostics
- Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α
- (2016) Yana G. Najjar et al. CLINICAL CANCER RESEARCH
- The CXCL8-CXCR1/2 pathways in cancer
- (2016) Qian Liu et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- (2016) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Tumor-Derived CXCL1 Promotes Lung Cancer Growth via Recruitment of Tumor-Associated Neutrophils
- (2016) Ming Yuan et al. Journal of Immunology Research
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
- (2015) Santiago Zelenay et al. CELL
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
- (2015) Sachet A Shukla et al. NATURE BIOTECHNOLOGY
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
- (2015) Thomas Powles et al. Journal for ImmunoTherapy of Cancer
- PD-L1 expression in nonclear-cell renal cell carcinoma
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases
- (2014) Remo C Russo et al. Expert Review of Clinical Immunology
- Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma
- (2014) S. Kusmartsev et al. JOURNAL OF IMMUNOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
- (2013) M. J. Brauer et al. CLINICAL CANCER RESEARCH
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Software for Computing and Annotating Genomic Ranges
- (2013) Michael Lawrence et al. PLoS Computational Biology
- Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs
- (2012) Christopher T. Saunders et al. BIOINFORMATICS
- Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses
- (2012) Kentaro Sumida et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets
- (2012) Andreas Wilm et al. NUCLEIC ACIDS RESEARCH
- The pro- and anti-inflammatory properties of the cytokine interleukin-6
- (2011) Jürgen Scheller et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- NetMHCcons: a consensus method for the major histocompatibility complex class I predictions
- (2011) Edita Karosiene et al. IMMUNOGENETICS
- The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo
- (2011) J. Yang et al. JOURNAL OF IMMUNOLOGY
- Fast and SNP-tolerant detection of complex variants and splicing in short reads
- (2010) T. D. Wu et al. BIOINFORMATICS
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
- (2009) M. D. Robinson et al. BIOINFORMATICS
- Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
- (2009) C. L. Roland et al. MOLECULAR CANCER THERAPEUTICS
- Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer
- (2009) Christina L. Roland et al. PLoS One
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
- (2008) Takuya Osada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now